Sign in Subscribe

Archive

A collection of 715 issues

Latest

Dynamic ctDNA Methylation Monitoring Guides Postoperative Surveillance in FIND Trial

Skip to content The CRC Digest ◆ TRIAL DATA Dynamic ctDNA Methylation Monitoring Guides Postoperative Surveillance in FIND Trial A prospective, randomized phase III trial tested whether circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer patients. (Journal of Clinical Oncology) This content is informational only and

CRC Research Update — July 31, 2026

Today's colorectal cancer research highlights

Physical activity and sedentary behavior linked to cortisol rhythms in CRC survivors up to 1 year after treatment

Skip to content The CRC Digest ♥ LIVING WITH CRC Physical activity and sedentary behavior linked to cortisol rhythms in CRC survivors up to 1 year after treatment Among 74 CRC survivors, accelerometer-assessed sedentary time and physical activity were longitudinally associated with diurnal cortisol patterns, which may influence fatigue, mood, and

Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition

Skip to content The CRC Digest ▸ TREATMENT Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition A 60-year-old male patient diagnosed in 2019 with BRAF-mutant metastatic CRC and peritoneal metastases experienced an extraordinary response to MEK inhibitor-based treatment. (Frontiers in Oncology) This content

Gut microbiome signatures show promise for non-invasive detection of colorectal neoplasia

Skip to content The CRC Digest ▪ SCREENING Gut microbiome signatures show promise for non-invasive detection of colorectal neoplasia Multinational metagenomic studies have identified reproducible microbial signatures associated with CRC, offering a potential alternative to current stool-based tests that have limited sensitivity for adenoma detection. (Journal of Gastroenterology) This content is

Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models

Skip to content The CRC Digest ▸ TREATMENT Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models Fruquintinib, an oral inhibitor of all three vascular endothelial growth factor receptors that has been approved for chemorefractory CRC, showed combined antitumor activity with TAS-102 in xenograft

Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status

Skip to content The CRC Digest ◆ TRIAL DATA Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status Research shows that patients with deficient mismatch repair or high microsatellite instability can benefit from immunotherapy even when they have poor performance status, a group often excluded from

Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery

Skip to content The CRC Digest ▪ SCREENING Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery The randomized trial found that circulating tumor DNA methylation monitoring identified recurrent metastatic disease with a more favorable and potentially resectable anatomical profile, significantly increasing the

CRC Research Update — July 30, 2026

Today's colorectal cancer research highlights

KRAS mutations drive immune evasion through RNA modifications

Skip to content The CRC Digest ◇ RESEARCH KRAS mutations drive immune evasion through RNA modifications Preclinical research found that KRAS mutations remodel RNA m6A modifications to increase CD73 expression, promoting immune evasion in colorectal cancer. (Cancer Research) This content is informational only and does not constitute medical advice. Always consult